Standard‐dose VKA plus single antiplatelet agent vs vitamin K antagonist (VKA)
Total mortalitya · people with antiphospholipid syndrome and a history of stroke or thromboembolic events
It is very uncertain whether standard‐dose VKA plus single antiplatelet agent changes all‐cause mortalitya compared with standard‐dose VKA (very low certainty).
1 finding from 1 review
- Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people… 2020 · Cochrane Headline outcomes onlyRR 0.49 [0.02, 11.68]1 study · 82 participantsVery low